WAVE Life Sciences Ltd., a genetic medicines company, announced that it has appointed Keith Regnante as the company’s chief financial officer.
Mr. Regnante joins WAVE with significant financial experience in leadership roles at life sciences companies.

Prior to joining WAVE, he was a Vice President of Finance at Shire where he oversaw finance for R&D, a global organization.

Prior to Shire, Mr. Regnante held a number of positions of increasing responsibility at Biogen, including leading the finance teams for Corporate Finance, R&D, and Business Development.

At Biogen, in addition to serving on the Investor Relations team, he served on teams that closed several significant, high-profile transactions, including the company’s merger with IDEC and its in-licensing and eventual acquisitions of the company’s multiple sclerosis drugs, Tysabri And Tecfidera.

Earlier in his career, Mr. Regnante was a Consultant with The Boston Consulting Group.

He received his MBA from the MIT Sloan School of Management and is a Phi Beta Kappa graduate of Tufts University with a BA in Economics. ■

• PTC appoints Corinna Lathan to board
• J.Jill appoints James S. Scully to board
• Raytheon elects Robert O. Work as director
• Xenetic Biosciences appoints three directors
• Insulet appoints two to board

---

More inside POST